

**Current Oncology Updates 2024**  
**Day 1 - 27th June 2024**  
**Time- 07:00 - 09:20 PM**

<b>Time</b>	<b>Topics</b>	<b>Speaker</b>
07:00 - 07:05 PM	Welcome & Introduction	
07:05 - 07:15 PM	Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum	Dr. Nagendra Sharma
07:15 - 07:25 PM	Immunotherapy-Based Combinations in Intermediate HCC (Eligible for TACE)	Dr. Viraj, Ahmedabad
07:25 - 07:35 PM	Immunotherapy-Based Combinations as Adjuvant Therapy for High-Risk HCC	Dr Amol Patel
07:35 - 07:50 PM	Immunotherapy in Advanced/Metastatic HCC	Dr. Vamshi Krishna
07:50 - 08:10 PM	Panel discussion: Latest Updates on (Neo)Adjuvant and 1L Systemic Therapy for Advanced/Metastatic NSCLC	Dr. Bhuwan Chug
08:10 - 08:20 PM	Guideline recommendations for stages IIIA-C and IV NSCLC	Dr. Sumant Gupta
08:20 - 08:30 PM	Recommendations for EGFR-mutated NSCLC	Dr. Anshul Gupta
08:30 - 08:40 PM	Recent clinical trial data for: EGFR alterations (eg, deletions, mutations, or insertions) Considerations for Advanced/Metastatic NSCLC With Central Nervous System Metastases	Dr. Vikas Asathi
08:40 - 08:50 PM	EGFR TKI Mechanisms of Resistance	Dr. Pooja Babbar

8:50 - 09:00 PM	Known EGFR mutations affecting EGFR TKI efficacy	TBC
09:00 - 09:10 PM	Systemic therapies for EGFR TKI therapy-resistant/refractory disease Current guidelines	Dr. Naresh Somani
09:10 - 09:20 PM	Outcomes for systemic therapy in nonsquamous and/or squamous NSCLC	Dr. Yashwant Raipur
09:20 PM Onwards	Closing Remarks	

**Current Oncology Updates 2024**  
**Day 2 - 28th June 2024**  
**Time- 07:00 - 09:20 PM**

<b>Time</b>	<b>Topics</b>	<b>Speaker</b>
07:00 - 07:05 PM	Welcome & Introduction	
	<b>Prostrate Cancer</b>	
07:05 - 07:15 PM	Molecular Biomarker Testing in Patients With Prostate Cancer: Challenges and Recommendations	TBC
07:15 - 07:25 PM	Aligning Prostate Cancer Clinical Practice With Recent Findings and Expert Recommendations Regarding PARP Inhibitor-Based Combination Regimens	Dr. Chandragouda
07:25 - 07:32 PM	CONTACT-02: Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer	Dr. Chitresh Aggawal
	<b>Urothelial Cancer</b>	

07:32 - 07:39 PM	Erdafitinib and Enfortumab Vedotin Sequencing in Patients With FGFR2/3-Altered aUC: UNITE Database Retrospective Analysis	Dr. Aditya Murli, Bangalore
07:39 - 07:46 PM	Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma	Dr. Manish Sharma
07:46 - 08:01 PM	Sponsored Talk : Merck	
08:01 - 08:26 PM	Panel : Management of Advance UC	Dr. Rajat Bajaj
	RCC	
08:26 - 08:36 PM	Current Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC)	Dr. Trivikram Rao
08:36 - 08:56 PM	Panel : Management of Mrcc	Dr. Randeep Singh
08:56 PM Onwards	Closing Remarks	